Prevention of meningococcal serogroup C disease by NeisVac-C™

References

• Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J. Infect. Dis.180, 1894–1901 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med.344, 1378–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Branham SE. Serological relationships among meningococci. Bacteriol. Rev.17, 175–188 (1953).
   PubMedGoogle Scholar
• Vedros NA. Development of meningococcal serogroups. In:Evolution of Meningococcal Disease. Vedros NA (Ed.).CRC Press Inc., FL, USA 33–37 (1987).
   Google Scholar
• Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Vaccines (5th Edition) Plotkin SA, Offit P, Orenstein WA (Eds).WB Saunders Company, PA, USA 399–434 (2008).
   Google Scholar
• Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis.188, 481–485 (2003).
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm. Rep.54, 1–21 (2005).
   PubMedGoogle Scholar
• Schmitt HJ, Maechler G, Habermehl P et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae–Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol.14, 426–434 (2007).
   PubMedGoogle Scholar
• Snape MD, Pollard AJ. Meningococcal polysaccharide–protein conjugate vaccines. Lancet Infect. Dis.5, 21–30 (2005).
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines5(6), 851–857 (2006).
   PubMed Web of Science ®Google Scholar
• De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev. Vaccines5(2), 269–275 (2006).
   PubMed Web of Science ®Google Scholar
• Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel)103, 151–160 (2000).
   PubMedGoogle Scholar
• Lee S-M, Petermann R, Porte Q, Berezuk G, Crowe B, Shirtz J. Long-term thermal stability of group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine. Hum. Vaccin.3, 27–32 (2007).
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch. Dis. Child.92, 909–915 (2007).
   PubMed Web of Science ®Google Scholar
• Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ333, 571 (2006).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC).Inadvertent misadministration of meningococcal conjugate vaccine – United States, June–August 2005. MMWR Morb. Mortal. Wkly Rep.55, 1016–1017 (2006).
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: II. Development of natural immunity. J. Exp. Med.129, 1327–1348 (1969).
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection – serum bactericidal antibody activity. Vaccine23, 2222–2227 (2005).
   PubMed Web of Science ®Google Scholar
• Griffis JM, Goroff DK. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol.130, 2882–2885 (1983).
   Google Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun.40, 257–264 (1983).
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Infect. Immun.69, 1568–1573 (2001).
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Clin. Diag. Lab. Immunol.10, 780–786 (2003).
   PubMedGoogle Scholar
• Richmond P, Borrow R, Findlow J et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect. Immun.69, 2378–2382 (2001).
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Finn A et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C–tetanus toxoid conjugate vaccine in U.K. infants. Infect. Immun.71, 5549–5555 (2003).
   PubMed Web of Science ®Google Scholar
• Richmond PC, Miller E, Borrow R et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis.179, 1569–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Kitchin NR, Southern J, Morris R et al. Evaluation of a diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child.92, 11–16 (2007).
   PubMed Web of Science ®Google Scholar
• English M, MacLennan JM, Bowen-Morris JM et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine19, 1232–1238 (2000).
   PubMed Web of Science ®Google Scholar
• Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. Immunogenicity of meningococcal C conjugate vaccine conjugated to tetanus toxoid after each dose, given as a three-dose primary vaccination course in infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine24, 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5/Hib/IPV vaccine in healthy UK infants. Clin. Vaccine Immunol.16(2), 194–199 (2008).
   Google Scholar
• Kollaritsch H, Behre U. A randomized, open-label trial of Neisvac-C vaccine to evaluate immunological interference with hepatitis B, inactivated polio and acellular pertussis vaccines in healthy infants. Data on file: Baxter Bioscience (2002).
   Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated polio–Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C–tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J.25, 713–720 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T et al. Immunogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid vaccine (Hib–MenC–TT) following a 3, 5, 11 month schedule. Program and Abstracts of the 26th Annual meeting of the European society for Paediatric infectious Diseases – ESPID. Graz, Austria (2008) (Abstract 694).
   Google Scholar
• Tejedor JC, Moro M, Merino JM et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b–Neisseria meningitidis serogroup C–tetanus toxoid conjugate vaccine given to toddlers of 13–14 months of age with antibody persistence up to 31 months of age. Pediatr. Infect. Dis. J.27, 579–588 (2008).
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D et al. Ability of three different meningococcal C conjugate vaccines to induce immunological memory after a single dose in UK toddlers. J. Infect. Dis.183, 160–163 (2001).
   PubMed Web of Science ®Google Scholar
• Burrage M, Robinson A, Borrow R et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect. Immun.70, 4946–4954 (2002).
   PubMed Web of Science ®Google Scholar
• Richmond P, Goldblatt D, Fusco PC et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C–tetanus toxoid conjugate vaccine in healthy adults. Vaccine18, 641–646 (1999).
   PubMed Web of Science ®Google Scholar
• Southern J, Deane S, Ashton L et al. Effect of prior polysaccharide vaccination on magnitude, duration and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin. Diag. Lab. Immunol.11, 1100–1104 (2004).
   PubMedGoogle Scholar
• Borrow R, Southern J, Andrews N et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Vaccine19, 3043–3050 (2001).
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTaP–Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines7(1), 97–115 (2008).
   PubMed Web of Science ®Google Scholar
• Southern J, Gelb D, Andrews N et al. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, a month prior to or after, tetanus and diphtheria booster vaccinations. Hum. Vaccin.2, 237–242 (2006).
   PubMed Web of Science ®Google Scholar
• Medicines Control Agency/Committee on Safety of Medicines. Safety of meningococcal group C conjugate vaccines. Curr. Probl. Pharmacovig.26, 14 (2000).
   Google Scholar
• Andrews N, Stowe J, Miller E, Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum. Vaccin.3, 59–63 (2007).
   PubMed Web of Science ®Google Scholar
• Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Lancet362, 449–450 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor B, Andrews N, Stowe J, Hamidi-Manesh L, Miller E. No increased risk of relapse after meningococcal C conjugate vaccine in childhood nephrotic syndrome. Arch. Dis. Child.92, 887–889 (2007).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet357, 195–196 (2001).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364, 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the UK. J. Infect. Dis.194, 1745–1752 (2006).
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23, 4097–4100 (2005).
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J.25, 79–80 (2006).
   PubMed Web of Science ®Google Scholar
• Arnason S, Thors VS, Gudnason T, Kristinsson KG, Haraldsson A. [Bacteraemia in children in Iceland 1994–2005]. Laeknabladid94, 523–529 (2008).
   Google Scholar
• Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359, 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Ibarz-Pavon A, Urwin R, Maiden MC. The Meningococcal Carriage Group. Effect of the conjugate serogroup C–polysaccharide vaccine on the carriage and population structure of Neisseria meningitidis. Program and Abstracts of the 8th Meeting of the European Monitoring Group on Meningococci. Dublin, Ireland (2005) (Abstract 7.4).
   Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ326, 365–366 (2003).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol.162, 89–100 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis.9, 105–110 (1977).
   PubMed Web of Science ®Google Scholar
• De Wals P, Trottier P, Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine24, 3500–3504 (2006).
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Lewis S et al. Sero-protection against serogroup C meningococcal is more sustained following immunisation in the second decade of life than the first. BMJ336, 1487–1491 (2008).
   PubMed Web of Science ®Google Scholar